€6 M for drug development

€6 M for drug development

Newborn baby

Prophylix Pharma AS secure €6 M from EUs FP7 to develop the first drug able to prevent severe bleedings in foetuses and newborns due to foetal/neonatal alloimmune thrombocytopenia (FNAIT).

http://www.prophylixpharma.com/news-and-links/news/